Cochrane · systematic review · CD008525
Antidepressants for depression in adults with HIV infection
Eshun‐Wilson, I, Siegfried, N, Akena, DH, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
15
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 46.7%Low 7 · 46.7%Moderate 1 · 6.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antidepressant compared to placebo for depression in adults with HIV infection
Population: adults living with HIV and depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous; standardized mean difference) Antidepressant vs placebo | no estimate extracted | 6 studies · 357 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Improvement in depression: HAM‐D score at 6‐12 weeks (dichotomized) Antidepressant vs placebo | RR 1.1 [0.89, 1.35] | 5 studies · 434 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) Antidepressant vs placebo | RR 1.28 [0.93, 1.77] | 4 studies · 346 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Study dropouts at 6‐12 weeks Antidepressant vs placebo | RR 1.28 [0.91, 1.8] | 4 studies · 306 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects during antidepressant treatment period (0‐12 weeks) Antidepressant vs placebo | RR 0.88 [0.64, 1.21] | 2 studies · 167 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life score at 8 weeks Antidepressant vs placebo | no estimate extracted | 1 study · 87 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Selective serotonin reuptake inhibitors (SSRI) compared to tricyclic antidepressant (TCA) for depression in adults with HIV infection
Population: adults living with HIV and depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in depression: HAM‐D score at 6‐12 weeks (continuous) Selective serotonin reuptake inhibitors (SSRI) vs tricyclic antidepressant (TCA) | no estimate extracted | 1 study · 14 participants | Very low Downgraded: risk of bias |
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) Selective serotonin reuptake inhibitors (SSRI) vs tricyclic antidepressant (TCA) | RR 0.89 [0.54, 1.46] | 2 studies · 64 participants | Very low Downgraded: risk of bias |
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) Selective serotonin reuptake inhibitors (SSRI) vs tricyclic antidepressant (TCA) | RR 1.24 [0.68, 2.24] | 2 studies · 64 participants | Very low Downgraded: risk of bias |
Study dropouts at 6‐12 weeks Selective serotonin reuptake inhibitors (SSRI) vs tricyclic antidepressant (TCA) | RR 0.81 [0.51, 1.3] | 2 studies · 64 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects during antidepressant treatment period (0‐12 weeks) Selective serotonin reuptake inhibitors (SSRI) vs tricyclic antidepressant (TCA) | RR 1.05 [0.67, 1.64] | 1 study · 14 participants | Very low Downgraded: risk of bias |
Selective serotonin reuptake inhibitor (SSRI) compared to atypical agent for depression in adults with HIV infection
Population: adults living with HIV and depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) Selective serotonin reuptake inhibitor (SSRI) vs atypical agent | no estimate extracted | 1 study · 70 participants | Low Downgraded: imprecision |
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) Selective serotonin reuptake inhibitor (SSRI) vs atypical agent | RR 0.94 [0.79, 1.11] | 1 study · 70 participants | Low Downgraded: imprecision |
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) Selective serotonin reuptake inhibitor (SSRI) vs atypical agent | RR 0.78 [0.52, 1.17] | 1 study · 70 participants | Low Downgraded: imprecision |
Study dropouts at 6‐12 weeks Selective serotonin reuptake inhibitor (SSRI) vs atypical agent | RR 1.67 [0.43, 6.45] | 1 study · 70 participants | Low Downgraded: imprecision |